Novo Nordisk To Challenge Russian Competition Fine

Law360, New York (September 27, 2010, 4:27 PM EDT) -- Novo Nordisk A/S is planning to challenge a decision by Russia's competition authority to fine the insulin maker for allegedly limiting competition in the pharmaceutical market.

The company will challenge the decision by Russia’s Federal Antimonopoly Service in the Commercial Court of the City of Moscow, Novo Nordisk spokeswoman Katrine von Rud Sperling said Monday.

That revelation came just a few days after the Russian competition authority said it would fine a unit of the Danish pharmaceutical company, the largest insulin maker in the world, for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.